Dr. Jung Min Lee, M.D.

Jung-Min Lee, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Women's Malignancies Branch


Dr. Lee’s research focuses on developing targeted therapies for ovarian carcinoma. Her studies have identified key proteins of DNA damage response pathways as therapeutic targets, opening up possibilities for novel therapies for this disease. Her research also emphasizes the collection of patient samples to better understand treatment response and tumor biology in gynecologic malignancies. Dr. Lee is the Principal Investigator of multiple investigator-initiated clinical trials and the Study Chair of multi-center Phase II/III clinical trials. 

Areas of Expertise

BRCA Mutation
Triple Negative Breast Cancer
Early Clinical Trials

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Key Publications

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCA-mutant ovarian cancer

Gupta N, Huang TT, Nair R J, An D, Zurcher G, Lampert J E, McCoy A, Cimino-Matthews A, Swisher M E, Radke R M, Lockwood M C, Reichel B Jonathan, Chiang CY, Wilson M K, Cheng CC K, Nousome D, Lee JM
Sci Transl Med. 15(701): 7802, 2023.
Full-Text Article
[ Journal Article ]

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Giudice E, Huang TT, Nair R J, Zurcher G, McCoy A, Nousome D, Radke R M, Swisher M E, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel B J, Lee JM
Nat Commun.. 15(1): 2805, 2024.
Full-Text Article
[ Journal Article ]

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Lampert J E, Zimmer A, Padget M, Cimino-Mathews A, Nair R J, Liu Y, Swisher M E, Hodge W J, Nixon B A, Nichols E, Bagheri H M, Levy E, Radke R M, Lipkowitz S, Annunziata M C, Taube M J, Steinberg M S, Lee JM
Clin Cancer Res.. 26(16): 4268-4279, 2020.
Full-Text Article
[ Journal Article ]

AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian Cancer

Huang TT, Chiang CY, Nair R J, Wilson M K, Cheng K, Lee JM
Cancer Research . 84(6): 887-904, 2024.
Full-Text Article
[ Journal Article ]

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

Nair J, Huang TT, Murai J, Haynes B, Steeg S P, Pommier Y, Lee JM
Oncogene. 39(33): 5520-5535, 2020.
Full-Text Article
[ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Staff Scientist
Tzu-Ting Huang, Ph.D.
Staff Scientist
Jayakumar Nair, Ph.D.
Investigator Trainee
Chi-Ting Shih, Ph.D.
Nurse Practitioner
Britanny Brooke Solarz , R.N., B.S.N.
Research Nurse
Ann McCoy, R.N.